Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22137606 | 0.94 | RET (0.52) | RETALDH1A1HSD17B10CYP3A4CYP2D6 | |
| SCHEMBL1780700 | 0.92 | RET (0.51) | RETALDH1A1HSD17B10CYP3A4CYP2D6 | |
| SCHEMBL29455974 | 0.92 | RET (0.51) | RETALDH1A1HSD17B10CYP3A4CYP2D6 | |
| SCHEMBL30392218 | 0.91 | RET (0.51) | RETCYP11B2DDB1CRBNGPR119 | |
| SCHEMBL26100649 | 0.91 | RET (0.51) | RETCYP11B2DDB1CRBNGPR119 | |
| SCHEMBL23538928 | 0.91 | RET (0.49) | RETCYP11B2DDB1CRBNGPR119 | |
| SCHEMBL29744897 | 0.91 | RET (0.49) | RETCYP11B2DDB1CRBNGPR119 | |
| SCHEMBL29455847 | 0.90 | CYP11B2 (0.56) | RETCYP11B2DDB1CRBNGPR119 | |
| SCHEMBL14161243 | 0.86 | RET (0.51) | RETALDH1A1HSD17B10CYP3A4CYP2D6 | |
| SCHEMBL594352 | 0.86 | AKR1C3 (0.57) | RETHPGDDDB1CRBNGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025061029-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2025-03-27 | — | — | WO | disclosed |
| EP-2102208-B1 | NOVEL SUBSTITUTED DIAZA SPIRO PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-23 | — | — | EP | disclosed |
| US-8158643-B2 | Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-8158643-B2 | Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
| WO-2008068265-A1 | NOVEL SUBSTITUTED DIAZA SPIRO PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | MCHR1, MCHR2, MC1R | RET 1540/4885ALDH1A1 281/4885HSD17B10 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.